Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES PET as a Predictive Measure for Endocrine Therapy in Metastatic Breast Cancer
NCT02398773Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoroestradiol f 18 in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Negative Predictive Value of FES Uptake for Response at 6 months. Started May 2016; status: active, not recruiting.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02398773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398773.